Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin
- Institution
- UNIVERSITY OF ILLINOIS AT CHICAGO, IL
- Principal investigator
- Sarah Elizabeth Lutz
- Funding
- $2.5M
- Duration
- 2025–2029
Moonbase score
Still being scored
Abstract
Abstract COVID-19 increases the risk of vascular contributions to cognitive impairment and dementia (VCID). VCID is one of the most prevalent forms of dementia, so the potential public health impact of the COVID-19 pandemic on future VCID is substantial. However, the mechanisms by which COVID-19 modifies VCID are unknown. Identifying mechanisms that regulate how prior COVID-19 influences the brain endothelial cell response to vascular stress is important. Here, we provide preliminary evidence that COVID-19 decreases resistance to VCID by weakening the blood-brain barrier (BBB). This is accompanied by cerebrovascular inflammation. This grant will test the novel mechanism that SARS-CoV-2 infection accelerates VCID by suppressing cerebrovascular Wnt/β-catenin signaling. In Aim 1, we determine how prior SARS-CoV-2 infection influences BBB permeability and cognition upon subsequent vascular insult, by genetic and epigenetic modification. In Aim 2 we use endothelial-targeted genetic interventions to assess the contribution of Wnt/β- cat targets to resistance to post-infectious VCID. In Aim 3, we ask whether established post-infectious VCID can be reversed by increasing cerebrovascular Wnt/β-catenin. These studies could lead to novel approaches to identify individuals at high risk for VCID and novel potential therapeutic strategies to mitigate the impact of prior infection on the development of dementia.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF ILLINOIS AT CHICAGO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Illinois at ChicagoNot yet scored
Targeting cerebrovascular Wnt/beta-catenin signaling to reverse brain endothelial damage induced by SARS-CoV-2 infection
Sarah Elizabeth Lutz · $801K · 2024–2029
- NIH · University of Illinois at Chicago47
MASLD protection by STAT5-regulated transcription factors
Rhonda D Kineman · $825K · 2025–2030
- NIH · University of Illinois at Chicago47
Identifying a novel pathway that regulates RA immunometabolism
Shiva Shahrara · $715K · 2022–2028